Market price of tremelimumab

Tremelimumab is an immune checkpoint inhibitor targeting CTLA-4. It enhances the body's anti-tumor immune response by releasing the inhibitory signals of T cells. This mechanism makes it show potential value in the treatment of a variety of advanced or refractory tumors, especially in combination immunotherapy, where it can synergize with PD-L1 inhibitors such as durvalumab to enhance T cell activity, thereby improving the patient's treatment response rate. For patients with unresectable hepatocellular carcinoma (uHCC) and specific subtypes of non-small cell lung cancer (NSCLC), the combined use of temsitumumab can improve the disease control rate and prolong the disease stable period, while providing a new option for patients who have failed to respond to standard treatments.

In addition to its therapeutic effect, the advantages of temsitumumab in clinical applications include its precise effect on specific immune pathways. Compared with traditional chemotherapy, it does not directly kill tumor cells, but activates the body's own immune system to form continuous immune surveillance of tumors, which may reduce chemotherapy-related toxicity and provide patients with long-term survival benefit potential. In advanced or relapsed patients, the addition of temtumumab can become an important part of the treatment plan. Especially in immune combination strategies, the balance between its efficacy and safety has attracted great clinical attention.

Currently, temsitumumab is not yet available in mainland China, so domestic patients are temporarily unable to obtain the drug through formal channels, and it cannot be included in medical insurance reimbursement. In the overseas market, temsitumumab has been approved for use in the United States, Europe and some Asian regions. Its specification is 300mg/15ml. The market price is about 100,000 yuan, which is relatively expensive. There are currently no generic drugs or domestically produced temsitumumab that can replace the original drug, so there are certain limitations in accessibility, and patients need to obtain treatment through formal overseas channels or clinical trials.

Reference: https://www.drugs.com/mtm/tremelimumab.html